A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

Penny Ward MBBS, FFPM - Chief Medical Officer

Penny has over two decades of experience in clinical development and medical affairs, having held senior management/therapeutic area head roles in Pharmacia and Upjohn, Roche, GSK and UCB. She was previously CMO at Novimmune, Glenmark and Topivert. As owner and of private consulting company, PWG Consulting (Biopharma) Ltd she has been serving as Chief Medical Officer of Karus Therapeutics since 2013, as well as consulting to other biopharmaceutical companies and investment groups. Penny’s work has enabled the approval of multiple products (small molecules and biologics) for the treatment of infectious diseases, osteoporosis, cancer and autoimmune disorders in the US, EU and Japan, OTC switches and the development and approval of diagnostics, most recently the novel PET tracer Axumin®, in the US and EU.